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Abstract
Tauopathies are a heterogeneous group of pathologies characterized by tau aggregation inside neurons. Most of them
are sporadic but certain tauopathies rely on tau gene (MAPT) mutations. They particularly differ from one to another by
their different neuropathological signatures e.g. lesion shapes, regions affected and molecular composition of
aggregates. Six isoforms of tau exist, but they do not all co-aggregate in each tauopathy but rather have a unique
signature for each one. In some tauopathies such as Alzheimer’s disease (AD), tau protein aggregation follows
stereotypical anatomical stages. Recent data suggest that this progression is due to an active process of tau protein
propagation from neuron-to-neuron. We wondered how tau isoforms or mutations could influence the process of tau
aggregation and tau propagation. In human neuropathological material, we found that MAPT mutations induce a
faster misfolding compared to tau found in sporadic AD patients. In the rat brain, we observed cell-to-cell transfer of
non-pathological tau species irrespective of the tested isoform or presence of a mutation. By contrast, we found that
the species of tau impact the propagation of tau pathology markers such as hyperphosphorylation and misfolding.
Indeed, misfolding and hyperphosphorylated tau proteins do not spread at the same rate when tau is mutated, or the
isoform composition is modified. These results clearly argue for the existence of specific folding properties of tau
depending on isoforms or mutations impacting the behavior of pathological tau species.
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Introduction
Tau is a microtubule-associated protein mainly found in
the axonal part of neurons. Resulting from an alternative
splicing mechanism, six major isoforms of tau coexist in
the human brain with the presence of either 3 or 4 re-
peated sequences (named below as 3R-tau or 4R-tau)
known as the microtubule-binding regions [8, 28]. The
hyperphosphorylation and deposition of tau proteins in
insoluble aggregates inside neurons are a hallmark of
around 20 pathologies called tauopathies including the
well-known Alzheimer’s disease (AD) [8, 25]. These ag-
gregates progressively invade the whole neuron and form
specific intraneuronal lesions named neurofibrillary de-
generation (NFD) ultimately leading to cell death. How-
ever, the kinetics of this pathological cascade as well as
the exact factors leading to cell death are still poorly
understood [61]. Furthermore, even if tauopathies share
common features, this group of pathologies is very het-
erogeneous with a vast variety of clinical presentations
including fronto-temporal dementias (e.g. Pick’s disease
(PiD)), movement disorders/parkinsonism (e.g. progres-
sive supranuclear palsy (PSP)) or Alzheimer’s type de-
mentia such as AD or argyrophilic grain disease (AGD)
[39]. This heterogeneity may be explained by strong
histopathologic differences and differential laminar and
regional brain distribution but also by molecular varia-
tions such as isoform composition and posttranslational
modifications. For example, in AD, the six isoforms of
tau co-aggregate, in contrast to pathologies like PSP or
AGD, in which only the 4R-tau isoforms aggregate, and
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Pick’s disease, where the aggregates are only comprised
of 3R-tau [39]. Adding additional complexity, around 50
autosomal dominant mutations in the tau gene (MAPT)
have been reported to promote strong tau aggregation
and clinically lead to dramatic fronto-temporal lobar de-
generation (formerly FTDP-17 now referred to as gen-
etic FTLD-Tau) [21, 23].
Likely due to the molecular heterogeneity of tauopa-
thies, different morphologies of lesions can be observed,
with mainly flame-shaped neurofibrillary tangles in AD,
argyrophilic grains and/or glial lesions in AGD or PSP
and Pick bodies in Pick’s disease [39]. These lesions
affect different part of the brain and the pathology
evolves differently. Thus, histopathological studies in
some sporadic tauopathies such as AD [6, 15, 24], PSP
[66, 69] and AGD [55] show that, specifically for each
disease, tau lesions appear progressively and hierarchic-
ally in the brain along anatomical connections. The
mechanisms underlying such evolution had remained
unexplained for many years and are still poorly under-
stood [60]. Increasing evidence both in vitro and in vivo,
support the ideas that the evolution across brain areas is
the result of the active propagation of NFD within the
brain. Indeed, our group and others recently showed
that tau assemblies are transferred from cell-to-cell and,
by being taken up by a second cell, seed the aggregation
of endogenous tau leading to the propagation of tau le-
sions in the brain [13, 14, 19, 57, 65] reviewed in [48].
Interestingly, in these studies, 4R-tau human con-
structs were always used to observe tau propagation/
seeding. In human tauopathies, the spatio-temporal evo-
lution of NFD was also only reported in three sporadic
tauopathies in which the 4R-tau isoforms aggregate (AD,
AGD and PSP). Conversely, it is still controversial
whether 3R-tau can propagate in genetic FTLD-Tau
(mutant tau) or Pick’s disease (3R-tau) [33].
Phosphorylation plays essential roles in tau physiology
particularly by controlling its binding with microtubules
[5, 49]. In AD, tau hyperphosphorylation leads to the
misfolding of tau protein and its oligomerization in
highly structured, insoluble aggregates [3]. Nowadays,
this hypothesis has been widened to all human tauopa-
thies. Tau misfolding is thought to be responsible for the
seeding propensity of tau that ultimately becomes aggre-
gated and insoluble [45]. This sequence of event is how-
ever not yet completely clear and some intriguing data
obtained with a transgenic mouse model overexpressing
mutant tau strongly suggest that the appearance of the
epitopes of misfolding (particularly with the antibodies
Alz50/MC1) precede hyperphosphorylation (particularly
with the antibody AT8) [29]. Interestingly, in genetic
FTLD-Tau (mutant tau), tau proteins show conform-
ational changes even without hyperphosphorylation [35,
46, 67, 68]. In the present study, we re-explore these
issues in human neuropathological samples and experi-
mentally in a rat model, to understand how isoforms
and mutations influence tau propensity to misfold and
propagate from neuron-to-neuron.
We analyzed NFD by immunohistochemistry in differ-
ent brains areas from genetic FTLD-Tau (3 different mu-
tations) and AD patients (at different Braak stages) using
either conformation-dependent or phospho-dependent
antibodies. Conformational changes might occur before
hyperphosphorylation only in genetic FTLD-Tau patients
and not in AD. To further explore these observations,
we used a rat model of tauopathies [10, 19], to examine
the pathophysiological propagation of tau using different
species, 3R or 4R, mutant or wild-type (WT). As previ-
ously described, 4R-tau propagates physiologically and
pathologically from neuron-to-neuron to distant brain
areas [19]. Interestingly, when mutant or 3R-tau con-
structs are used, the transfer of non-pathological species
of tau remains functional but tau pathology does not
spread and stays in the vicinity of the initiation site. Early
conformational changes as indicated by the MC-1 immu-
noreactivity might facilitate aggregation and neurodegen-
eration rather than propagation. Therefore, our results
suggest that different tau species may encounter different
misfolding processes that could explain such differences.
Materials & methods
Viral vectors
The procedures to produce the lentiviral vectors (LVs)
batches have been previously described [10, 16, 31].
Briefly, the packaging construct pCMVΔR8.92, the
pRSV-Rev, pMD.2G and the human Tau cDNA
(htau1N4R, htau1N4R-P301L, htau1N4R-P332S, htau1
N3R or htau1N3R-P332S) were co-transfected in human
293T cells and lentiviral vectors particles were concen-
trated from successive ultracentrifugation of the culture
medium 48 h later.
Animals
Wistar male rats were purchased from Janvier Laborator-
ies and housed in a temperature-controlled room main-
tained on a 12 h day/night cycle with food and water
provided ad libitum. Animal experiments were per-
formed in compliance with and with the approval of the
local ethics committee (agreement 2015101320441671,
2016–2021), standards for the care and use of laboratory
animals, and the French and European Community
guidelines as well as the Massachusetts General Hospi-
tal’s Institutional Animal Care and Use Committee.
Stereotaxic injections, cerebro-spinal (CSF) and interstitial
fluids (ISF) sampling and sacrifice procedures
Rats were housed and stereotactically injected with PBS
or lentiviral vectors (LVs) (Coordinates from bregma:
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Anteroposterior − 5.3 mm, Mediolateral +/− 6.2 mm,
Dorsoventral − 7 and -6mm; for detailed procedures see
[19]) encoding either htau1N4R (n = 9 for histology, n = 3
for RNA extraction), htau1N4R-P301L (n = 5 for histology,
n = 3 for RNA extraction), htau1N4R-P332S (n = 6 for
histology, n = 3 for RNA extraction), htau1N3R (n = 8 for
histology, n = 3 for RNA extraction) or htau1N3R-P332S
(n = 5 for histology, n = 3 for RNA extraction). The nega-
tive control consists in injection of the vehicle (PBS, 1% v/
w BSA; n = 3 for histology, n = 3 for RNA extraction). For
histology analysis, eight months post-injection, animals
were deeply anesthetized (pentobarbital 50mg/kg) and
transcardially perfused first with cold 0.9% NaCl followed
by cold 4% PFA for 20min. The brains were immediately
removed, fixed overnight in 4% PFA, placed in 20% su-
crose for 24 h and frozen until further use. Free-floating
coronal cryostat sections (40 μm thickness) were used for
immunohistochemical analysis. For RNA extraction, 2
weeks post-injection, were deeply anesthetised (pentobar-
bital 50mg/kg). Brains were dissected, and 1-mm-thick
coronal sections were generated using an acrylic rat brain
matrix (Electron Microscopy Sciences). The sections were
immediately frozen on dry ice and stored at − 80 °C until
further use.
Immunohistochemistry
For rats, immunohistochemistry procedures were previ-
ously described [19]. Briefly, sections from the entire
brain were washed in PBS-0.2% Triton X-100 and
treated for 30 min with H2O2 (0.3%). Non-specific bind-
ing was blocked using goat serum (1:100 in PBS, Vector)
for 60 min. Sections were incubated overnight at 4 °C
with the monoclonal antibodies AT8 (Thermo Scientific;
MN1020–1:400; phosphorylated residues 202, 205 and
208 of tau) [42], ADx-215 [10, 54] (1:10,000; human spe-
cific total tau) or MC1/Alz50 (kind gifts from Dr. Peter
Davies – 1:10,000; misfolded tau) in PBS-0.2% Triton
X-100. After several washes, labelling was amplified by
incubation with an anti-mouse biotinylated IgG (1:400
in PBS-0.2% Triton X-100, Vector) for 60 min followed
by the application of the ABC kit (1:400 in PBS, Vector)
prior to visualization with 0.5 mg/ml DAB (Vector) in
Tris-HCl 50 mmol/L, pH 7.6, containing 0.075% H2O2.
Brain sections were counter-stained in a cresyl violet so-
lution (0.5%) and mounted with Vectamount (Vector)
for microscopic analysis.
For human sections, 9 μm thick paraffin-embedded
sections of hippocampus, temporal cortex and visual
cortex of 10 human cases (Table 1) were cut using a
microtome and placed on glass slides. Slides were incu-
bated at 55 °C for 4 h before being immerged in succes-
sive 8 min baths of xylene twice, EtOH 100% twice,
EtOH 95%, EtOH 70%, EtOH 50% and PBS three times.
Slides were then incubated in boiling citrate buffer (citric
acid anhydrous 10mM, Tween20 0.05%, pH = 6) in a
microwave at low power for 20 min. Slides were im-
merged in Tris-Buffered Saline (TBS) with 0.5% triton
X-100 for 30 min followed by blocking with TBS, 10%
Normal Goat Serum for 1 h. Slides were incubated over-
night at 4 °C with primary antibodies (Alz50, kind gift of
Dr. Peter Davis: 1/50 and AT8 1/400) in TBS, 5% NGS,
0.05% Triton X-100. Slides were washed 4 times with
TBS and then incubated with secondary antibodies
(anti-mouse IgM 568 and anti-mouse IgG 488 1/400,
Invitrogen) diluted in TBS, 5% NGS. Slides were washed
4 times with TBS and counterstained with Sudan black
(0.1% in 70% EtOH, filtered) for 20 min. Slides were
washed 4 times with TBS and coversliped with Fluoro-
mount G with Dapi (Thermo Fisher Scientific). Slides
were scanned using an Olympus VS-120 slide scanner
and then 100% of neurons were counted using the cell-
Sens software. All human tissues come from the Lille
Neurobank and the Massachusetts Alzheimer’s Disease
Research center and written consent forms have been
Table 1 Human case demographics
Case Age at death Sex (M/F) PMI (hours) Neuropathology diagnosis Braak stage (if applicable) MAPT mutation
(if applicable)
Neurobank
1 70 M 12 genetic FTLD-Tau N/A P301L Massachusetts ADRC
2 56 M 6 genetic FTLD-Tau N/A P301L Massachusetts ADRC
3 85 F 20 genetic FTLD-Tau N/A P332S Lille Neurobank
4 33 M 33 genetic FTLD-Tau N/A G389R Massachusetts ADRC
5 > 90 F 8 Control I N/A Massachusetts ADRC
6 68 M 27 Control I N/A Massachusetts ADRC
7 63 M 16 AD IV N/A Massachusetts ADRC
8 69 M 6 AD IV N/A Massachusetts ADRC
9 68 M 14 AD VI N/A Massachusetts ADRC
10 69 F 4 AD VI N/A Massachusetts ADRC
M Male, F Female, PMI Post Mortem interval, genetic FTLD-Tau genetic FrontoTemporal Lobar Dementia-Tau, AD Alzheimer’s Disease, N/A Non-Applicable
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obtained accordingly to the local legislations and ethical
committees. Human brains extracts were obtained from
the Massachusetts Alzheimer’s Disease Research Center
(grant number P50 AG005134, under IRB protocol
1999P003693) and the Lille Neurobank (CRB/CIC1403
Biobank, BB-0033-00030, agreement DC-2008-642) ful-
filling criteria of the local laws and regulations on bio-
logical resources with donor consent, data protection
and ethical committee review.
RNA extraction from brain sections and RT-PCR/PCR
The brain slices were lysed, and total RNA was extracted
using the RNeasy Lipid Tissue kit (Qiagen) according to
the manufacturer’s instructions and adjusted to 1 μg/mL.
RNA were retro-transcripted using the ‘High-capacity’
cDNA reverse transcription kit (Applied Biosystems);
cDNA was generated after reverse transcription of 1 μg
of RNA with 4 mM of dNTPs, 10X random primers, 1
units/ μl of RNAse inhibitor, 1.25 ng/μl of oligo dT, 2.5
units/μl of MultiScribe reverse transcriptase. Real time
PCR was then performed using the ‘Taqman gene ex-
pression Master Mix’ (Thermofisher) containing probe
against MAPT (ref probe: Hs00902194_m1). Results
were normalized to 18S transcripts (ref probe: 4308329).
Reactions and data analysis were carried out with a Ste-
pOnePlus thermocycler (Applied Biosystems).
Statistical assays
The P values have been determined using one-way
ANOVA tests and a Tukey post-hoc test or a Pearson’s
Chi-squared test with Yates’ continuity correction as in-
dicated in the figure legend. Differences were considered
to be statistically significant if p < 0.05.
Results
Differential misfolding/hyperphosphorylation profile in
human MAPT mutant carriers compared to sporadic AD
We hypothesized that the mechanisms of tau deposition
are different in sporadic tauopathies than when a
mutation of MAPT gene is present. Therefore, we inves-
tigated the presence of tau misfolding and hyperpho-
sphorylation epitopes in human brain samples. We
selected six Alzheimer’s disease patients (two Braak I,
two Braak IV, two Braak VI) and 4 patients with
Fronto-temporal dementia associated with a mutation of
MAPT gene (two P301L, one P332S and one G389R).
We stained brain sections from three different regions
following the Braak stages: hippocampus, temporal cor-
tex and visual cortex with AT8 antibody for tau hyper-
phosphorylation and Alz50 for tau misfolding. Three
different phenotypes can be observed: neurons positive
for both Alz50 and AT8 (Fig. 1a-c, arrows), neurons
positive only for AT8 (Fig. 1a-c, arrowheads) and, more
rarely, neurons positive only for Alz50 (Fig. 1a, star). We
quantified in each case the number of neurons in each
category. We counted a total number of 27,214 neurons
for the AD cases and 15,460 for the mutant cases. Most
of the neurons were positive both for tau misfolding and
hyperphosphorylation in all cases (AD: n = 17,588, mu-
tants n = 12,516 Fig. 1d, Additional file 1: Figure S1 and
Additional file 2: Table S1). The number of neurons with
only tau hyperphosphorylation was also prominent most
of the time (AD: n = 17,588, mutants n = 2731 Fig. 1d,
Additional file 1: Figure S1 and Additional file 2: Table
S1). More interestingly, we found significantly more
Alz50 positive-only neurons (213) in mutants compared
to only 4 in AD cases (only in the visual cortex of Braak
VI cases, Fig. 1d, Additional file 1: Figure S1 and Add-
itional file 2: Table S1). Distributions of frequencies of
both Alz50-only or AT8-only neurons were compared in
mutant versus AD using a Pearson’s Chi-squared test
with Yates’ continuity correction both globally (all re-
gions pooled) and in the hippocampus. Interestingly, and
taking into account the limitations of statistical analysis
on such heterogenous cohort with a small number of
cases, there is a significant link between having a muta-
tion and having Alz50-only positive neurons both overall
(p < .001; chi2 = 391) and in the hippocampus (p < .001;
chi2 = 656). There is also a significant link between hav-
ing a mutation and having AT8-only positive neurons
overall (p < .001; chi2 = 171) but not in the hippocampus
(p = 0.43; chi2 = .64). These results suggest that in AD,
hyperphosphorylation precedes or accompanies misfold-
ing in a large majority of neurons. By contrast, when the
MAPT gene is mutated, misfolding seems to precede
hyperphosphorylation in a small portion of neurons ar-
guing for folding differences of mutant tau proteins.
Cell-to-cell transfer of all tau species
We observe in human brains that hyperphosphorylation
seems to appear first in sporadic cases such as AD pa-
tients but appears after misfolding in genetic FTLD-Tau.
We next tested this hypothesis in an animal model. We
described, in a previous study, the transfer of human tau
proteins from the rat hippocampus to different distant
secondary regions including limbic or olfactive regions
following the injection of LVs encoding human wild-type
4R-tau [19]. Using this model of tau propagation, we
wanted to assess whether different tau species (mutant
tau and 3R-tau) act in a similar manner and also propa-
gates from neuron-to-neuron. Different cohorts of Wis-
tar male rats were bilaterally injected into the CA1 layer
of the hippocampus with LVs encoding the human
3R-tau or 4R-tau either mutant or WT. We selected two
different mutations: the widely used P301L only present
on 4R-tau isoforms and the mutation P332S present on
all isoforms [16] resulting in 5 different groups of ani-
mals referred above as 3R-tau, P332S-3R-tau, 4R-tau,
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Fig. 1 (See legend on next page.)
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P301L-4R-tau and P332S-4R-tau (Fig. 2a). We stained by
immunohistochemistry the brain sections with a human
specific N-terminal tau antibody (ADx215) in order to
properly discriminate the exogenous over-expressed tau
from the endogenous tau. With similar level of expres-
sion (Additional file 3: Figure S2) and no observable
retrograde transfer of the viral vectors [19], 8 months
post-injection, tau proteins can be detected in cell bodies
in various long-distance regions such as limbic areas,
cortical areas or olfactory area for all the tested groups
of animals (Figs. 2b-c). This transfer is particularly ob-
servable in the granular cell layer of the olfactory bulb
more than 10mm away from the injection site (Fig. 2c)
and in cortical caudal regions situated 3 mm behind the
injection (Fig. 2d). These data clearly indicate that all
species of tau, regardless of being 3R or 4R-tau, mutants
or WT, transfer from neuron-to-neuron.
Tau species-dependent differential propagation of tau
pathology
We previously highlighted major differences between
WT 4R-tau and P301L-4R-tau regarding hyperphosphor-
ylation, misfolding and aggregation in this rat model
[19]. The data we present above on human brains also
argue for a difference between WT and mutant tau in
the folding properties.
Based on these data, we investigated the impact of tau
isoforms and mutations on tau pathology spreading. We
stained the brain sections with epitopes of tau pathology:
hyperphosphoryled tau using the antibody AT8 [42, 44,
53] and misfolded tau using the antibody MC1 (IgG ver-
sion of Alz50 antibody, [34, 36]). We first verified that,
at the injection site, the focal overexpression of both
constructs resulted in the formation of tau pathology in
the CA1 of rats. 8 months post-injection, the neuronal
expression of all isoforms, either mutant or WT, results
in the formation of strong tau hyperphosphorylation
(Fig. 3a) and misfolding (Fig. 3b).
In order to understand how tau pathology spreads
through the brain, we analyzed the presence of tau le-
sions in the whole rat brain, from the olfactory bulb
(rostro-caudal coordinates + 6 mm from bregma in cor-
onal sections) to the end of the cortical areas
(rostro-caudal coordinates − 9 mm from bregma in cor-
onal sections). As a sensor for tau pathology spreading
from the initiation site to secondary regions, we deter-
mined for each animal the rostral-most and caudal-most
coordinates where we could see tau pathology, either in
neurites or in cell bodies. We confirmed our previous
data showing that in rats injected with LVs encoding
4R-tau the AT8 immunoreactivity was found in the cell
body of second order neurons in several connected re-
gions (e.g. the granular layer of the olfactory bulb) as far
as 11 mm away from the injection site. Interestingly, in
rats injected with LVs encoding P332S-4R-tau,
P301L-4R-tau, 3R-tau or P332S-3R-tau, AT8 immunore-
activity was significantly restricted to the vicinity of the
initiation site both for neurites or cell bodies (Fig. 3c).
In order to compare the appearance of tau hyperpho-
sphorylation and tau misfolding in our model, we also
stained by immunohistochemistry the epitope of mis-
folding MC1 in the different cohorts of rats. We deter-
mined the rostral-most and caudal-most coordinates for
each animal to be able to compare the spatial appear-
ance of MC1 epitope and of AT8 epitope. In the animals
overexpressing the WT proteins 3R-tau and 4R-tau, the
MC1 immunolabelling stayed significantly closer to the
initiation site than the AT8 immunolabelling (Fig. 3d).
Indeed, numerous brain regions show hyperphosphory-
lated tau without misfolding tau. It is really intriguing to
notice that when a mutant tau species is overexpressed,
the MC1 immunolabelling is retrieved in regions signifi-
cantly more (or equally for P301L) distant from the initi-
ation site than the AT8 immunolabelling (Fig. 3d) clearly
suggesting a difference between WT proteins and mu-
tant proteins in terms of tau misfolding and hyperpho-
sphorylation in the context of spatial spreading.
Discussion
The data in the present study reveal new aspects of the
propagation of tau proteins by demonstrating that differ-
ent species of tau have different behaviors in terms of
pathological spreading and folding properties. Since the
discovery of tau protein as the principal component of
NFD [7, 26], around 20 pathologies involving aggregated
tau were described with various time-courses, lesions
(See figure on previous page.)
Fig. 1 Tau misfolding and hyperphosphorylation in human brains with AD and genetic FTLD-Tau. (a, b and c) human brain sections from a
genetic FTLD-Tau case (a), a Braak IV AD case (b) and a Braak VI AD case (c) stained with AT8 (green), Alz50 (red) and Dapi (blue) showing
neurons Alz50 and AT8 positive (arrows), neurons only AT8 positive (arrowhead) and neurons only Alz50 positive (star). Scale bars represent
20 μm (d) Quantification of the percentage of neurons single or double positive for Alz50 and AT8 in MAPT mutants (n = 4, top panels) or AD
cases (n = 6, low panels) in hippocampus (left), temporal cortex (middle) and visual cortex (right). The percentages for each category: double
positive (brown), AT8 only (green) and Alz50 only (red) are indicated along with standard deviations. Statistical test used: Pearson’s Chi-squared
test with Yates’ continuity correction was used to assess the distribution of Alz50-only neurons and AT8-only neurons in mutant versus AD cases.
The presence of Alz50-only positive neurons was significantly linked to the presence of a MAPT mutation both taking into account all regions (p
< .001; chi2 = 391) and in the hippocampus (p < .001; chi2 = 656). The presence of AT8-only positive neurons could only be linked with the
presence of a mutation taking into account all regions (p < .001; chi2 = 171)
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Fig. 2 All tau species are transferred from neuron-to-neuron. (a) Schematic representations of tau construct used in this study. (b) Schematic
representation of rat brain showing the injection coordinates in red and some of the rostral-most and caudal-most regions where we can find
tau propagation. (c and d) Rat brains sections at coordinates + 5.7 mm (c) -8.3 mm (d) from bregma stained with a total human tau antibody
(Adx215) showing transfer of tau for every species. htau1N4R (n = 9), htau1N4R-P301L (n = 5), htau1N4R-P332S (n = 6), htau1N3R (n = 8) or
htau1N3R-P332S (n = 5). Scale bars represent 20 μm
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and involved tau species [39]. This group includes path-
ologies with aggregated 3R-tau, 4R-tau, or both isoforms.
Rare fronto-temporal dementia cases also involve muta-
tion in the tau gene [23]. These latter proteins are
pro-aggregative [4, 12] often showing strong tau path-
ology when overexpressed and therefore are widely used
in the modelling of tau pathologies [18]. The in vivo
studies dealing with tau propagation are also mainly
based on the overexpression or injection of mutant
4R-tau proteins [1, 13, 14, 32, 41, 63]. However, in view
of the neuroanatomical and biochemical differences
among human tauopathies [2, 4, 22], one may ask if the
different tau species trigger the same pathological
mechanisms.
Here, we studied the misfolding and hyperphosphory-
lation status of tau proteins in human brains with AD or
with MAPT mutations. In all groups, we found a major-
ity of tangles showing both misfolding and hyperpho-
sphorylation and also a high number of neurons
showing only hyperphosphorylation. More interestingly
though, the misfolding-only neurons were most preva-
lent in mutant tau brains (Fig. 1). This result doesn’t
show per se that tau misfolding precedes hyperpho-
sphorylation in MAPT-mutant patients and the contrary
Fig. 3 Differential of spreading of tau pathology between tau species. (a and b) Rat brains sections at − 5.3 mm from bregma for each group
labelled with AT8-hyperphosphorylated tau antibody (a) or MC1-misfolded tau antibody (b) and showing strong tau pathology at the injection
site. Scale bars represent 40 μm (c and d) Distribution of the AT8 (c) or MC1 (d) staining in coronal sections throughout the brains for each
group is represented with bars along the scale of antero-posterior coordinates from Bregma. Bars represents the average of rostral-most to
caudal-most staining (cell body or neurite) observed for each cohort. Red stars represent the coordinate of the last cell body observed. htau1N4R
(n = 9), htau1N4R-P301L (n = 5), htau1N4R-P332S (n = 6), htau1N3R (n = 8) or htau1N3R-P332S (n = 5). The mean and standard deviations are
indicated at the end of each bars. Statistical test used: One-way ANOVA test followed by a Tuckey post-hoc test was used to assess statistical
differences between each group
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in AD patients but seems to indicate that the
mutant-tau may have different folding properties com-
pared to WT tau.
To model such differences, we took advantage of lenti-
viral technology to induce the accumulation of 3R or 4R
WT or mutant tau, and to investigate the propagation of
both the protein and the pathology. We show that regard-
less of the isoform or mutation, all tau proteins are cap-
able of long-distance propagation through the brain (Fig.
2) consistent with the existence of a cell-to-cell transfer
mechanism as previously suggested [14, 19, 41]. Our study
indicates that most of the tau species, travel in a
non-pathological, non-phosphorylated, non-misfolded
state. Indeed, we clearly see transfer for every species stud-
ied (Fig. 2) but only some of them show long distance
pathological epitopes presence (Fig. 3). It is clear in this
model that at least part of tau cell-to-cell transfer is
physiological, as tau does not seem to be either misfolded
or hyperphosphorylated. This finding is in line with nu-
merous studies showing that secreted tau is mostly mono-
meric and non-phosphorylated [11, 17, 37, 38, 47, 50–52,
56, 58, 62, 64, 70].
We also show differences in tau pathology between
species of tau in the human brains (Fig. 1). Therefore,
we wondered if, in the rat model, the propagation of
pathological epitopes is impacted by the species. Indeed,
all constructs trigger the development of tau pathology
in the hippocampus of rats, but these pathologies evolve
in a different manner in the whole brain. 4R-tau leads to
a strong long-distance spreading of tau pathology when
3R-tau or mutant-tau mediated-pathologies stay in the
vicinity of the pathology initiation site and don’t spread
in long-distant brain areas (Fig. 3). These observations
using mutant tau confirm our previous data obtained
with the P301L mutation [19], located in the 2nd tau re-
peat, and extend our conclusions to another genetic
FTLD-Tau mutation located in the 3rd tau repeat [16].
Given the reproducibility of our results among several
cohorts of animals, as well as our observations in human
brains, such differences between WT-4R-tau and 3R-tau
or mutant-tau are likely to be due to intrinsic properties
of mutant tau proteins. First, both mutant-tau and
3R-tau are known to induce better fibrillogenesis than
WT-4R-tau [12, 59] probably due to conformational
changes in the protein when tau protein is mutated [2,
20, 22]. For 3R-tau, the presence of a single cysteine in
its sequence allows for the formation of intermolecular
bridges initiating tau conversion/aggregation. Con-
versely, the two cysteines (C291, C322) present in 4R tau
mostly drive the formation of intramolecular bridges,
potentially slowing-down the process of oligomerization
and subsequent aggregation [59].
Indeed, in this study, we suggest that 3R-, 4R- or
mutant-tau support different types of pathological
conversion. The classical view regarding the pathological
conversion of tau proteins from a disordered state to in-
soluble, ordered and hyperphosphorylated aggregates
suggests that tau becomes hyperphosphorylated indu-
cing first the misfolding of the protein, and then its
oligomerization. This hypothesis is further supported by
the early appearance during the pathology of certain epi-
topes of phosphorylation [3, 43]. However, recently, Dia-
mond’s team showed in a transgenic mouse model
overexpressing the mutant P301S-tau that the seeding
propensity of tau proteins is the first detectable indicator
of tau pathology, before misfolding (MC1 antibody) and
then hyperphosphorylation (AT8) [29]. We also previ-
ously reported the precocious appearance of tau misfold-
ing epitopes and not hyperphosphorylation when
mutant tau was overexpressed (As early as 2 months
post lentiviral vectors injection, see [10]). By contrast, it
is obvious that when overexpressing WT tau, hyperpho-
sphorylation occurs first at the initiation site [10] but
also in distant regions ([19], Fig. 3). Here, we confirm
that when mutant-tau proteins accumulate, tau may first
acquire misfolding properties (Figs. 1 and 3). This sup-
ports the existence of an intrinsic misfolding in
mutant-tau proteins leading to the early appearance of a
misfolding epitope and to the formation of fibrils with
different structures [2, 20, 22]. Interestingly, the struc-
ture of these fibrils is transmissible to other tau species
[20, 22]. This prominent misfolding might be the cause
of the higher toxicity and neurodegeneration reported
when mutant tau is expressed compared to WT [10, 30].
The phosphorylation state of tau may be a key player
in the propagation processes. We know that tau is
retained within axons due to its binding with microtu-
bules which is highly dependent on phosphorylation
[40]. Given that 3R-tau and mutant-tau show weaker
binding to microtubules compared to 4R-WT-tau [9, 16,
27], it is very unlikely for 3R-phospho-tau and
mutant-phospho-tau to stay in the axons. We
hypothesize that they relocalize to the soma and there-
fore be less available for trans-synaptic transfer than
4R-tau. These results also suggest the presence of differ-
ent tau species within the same individual (e.g.
non-phosphorylated tau, phosphorylated tau, misfolded
tau, truncated tau, dimers, oligomers, polymers,
seeding-competent tau) that act differentially for tau
transfer and pathological propagation. Most of them can
be called “tau pathological species” but it is rather diffi-
cult to clearly identify the role of each in the pathology.
In further studies, these different tau species should be
analyzed independently to understand the part of each
in the pathophysiological processes such as tau path-
ology spreading, misfolding or aggregation.
To conclude, the mechanisms of tau propagation and
cell-to-cell transfer are highly dependent on tau species
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and our study is the first to identify this differential pro-
pensity of tau isoforms/mutations to mediate tau path-
ology spreading. This observation probably relies on
intrinsic differences between tau species such as folding.
These characteristics are consistent with what is ob-
served in the human tauopathies and could explain their
phenotypic specificities. This study also highlights the
fundamental difference between tau physiological
cell-to-cell transfer and tau pathological propagation.
Those two mechanisms probably involve different spe-
cies of tau that behave differently in the brain. This con-
cept must be carefully taken into account and addressed
in further studies dealing with tau propagation.
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